AI-Generated Summary

The Trump administration has announced new tariffs, including a 100% duty on branded pharmaceutical products and 25% on heavy-duty trucks, set to take effect from October 1. These measures, justified to counter the 'FLOODING' of products, aim to incentivize domestic manufacturing and have already caused pharmaceutical company stocks across Asia to decline. The move is viewed as a significant shift in US trade policy, impacting market dynamics, investment plans, and potentially consumer prices.

In a nutshell

This policy represents a significant intervention in global pharmaceutical supply chains and market access, potentially increasing drug costs and compelling companies to reconsider manufacturing locations within the US. While aiming to boost domestic industry, it introduces considerable uncertainty and financial risk for international pharmaceutical firms and investors.

Source: Malayala Manorama